Moleculin Biotech, Inc., (MBRX) announced that it has entered into agreements with certain holders of its existing warrants for the immediate exercise of outstanding warrants to purchase up to 2,122,652 shares of common stock at an exercise price of $3.90 per share. The transaction is expected to generate approximately $8.3 million in gross proceeds before fees.
The closing of the warrant exercise is scheduled for February 20, 2026, subject to customary conditions. The company had a 1-for-25 reverse stock split on December 1, 2025.
MBRX is currently trading at $2.83, down 41.09%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.